NewAmsterdam Pharma Company N.V. NAMS
19.18 USD +0.18 (+0.95%)
At closeNov 10, 2026, 4:00 PM EST
19.18 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
18.90 Day range 20.04
17.90 52-week range 42.21
- YTD
- -45.32%
- 1 year
- -50.78%
News
globenewswire.com NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical…
benzinga.com Needham Maintains Buy on NewAmsterdam Pharma Co, Lowers Price Target to $46 Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and lowers the price target from $48 to $46.
zacks.com NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.5.- benzinga.com NewAmsterdam Pharma Q3 EPS $(0.14) Beats $(0.51) Estimate, Sales $19.164M Beat $7.340M Estimate NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.51) by 72 percent. This is a 77.05 percent increase over losses of…
globenewswire.com NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results – Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination), marking the first regulatory approval of obicetrapib…